Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
- 21 April 2005
- journal article
- clinical trial
- Published by Springer Nature in Diabetologia
- Vol. 48 (5), 838-848
- https://doi.org/10.1007/s00125-005-1732-4
Abstract
Long-term trials in insulin-treated subjects with type 2 diabetes have shown that adjunctive treatment with the amylin analogue pramlintide reduces HbA1c levels and elicits weight loss. While amylin reduces food intake in rodents, pramlintide’s effect on satiety and food intake in humans has not yet been assessed.Keywords
This publication has 49 references indexed in Scilit:
- Gastrointestinal Satiety Signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptideAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose‐timing studyDiabetes/Metabolism Research and Reviews, 2004
- Inhibition of Food Intake in Obese Subjects by Peptide YY3–36New England Journal of Medicine, 2003
- The Human Amylin Analog, Pramlintide, Reduces Postprandial Hyperglucagonemia in Patients with Type 2 Diabetes MellitusHormone and Metabolic Research, 2002
- The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned ratsInternational Journal of Obesity, 2001
- Amylin and Insulin Interact to Reduce Food Intake in RatsHormone and Metabolic Research, 2000
- Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.International Journal of Obesity, 1999
- Amylinʼs physiology and its role in diabetesCurrent Opinion in Endocrinology, Diabetes and Obesity, 1997
- Subdiaphragmatic vagotomy does not influence the anorectic effect of amylinPeptides, 1995
- Effects of Somatostatin on Human SatietyNeuroendocrinology, 1995